CNS Pharmaceuticals (NASDAQ:
CNSP) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $(6.00) by 73.67 percent. This is a 99.85 percent increase over losses of $(1.02 thousand) per share from the same period last year.